Dr. Mohammed Jahanzeb, MD provides Health-Related Quality of Life (HRQoL) Data in a Phase 3 Study of First-Line Brigatinib vs. Crizotinib in NSCLC (ALTA-1L).
Advertisement
Data in a Phase 3 Study of First-Line Brigatinib vs. Crizotinib in NSCLC (ALTA-1L)
